Growth Capital vs Patient Capital: Which Fits a Scaling Founder

Growth capital and patient capital are often set against each other as if a founder has to choose one, but they describe different things. Growth capital is a stage and structure of investment: typically a minority, non-control equity stake in an established, revenue-generating company, used to fund a specific expansion. Patient capital is a time horizon and intent: long-term finance that prioritises durable growth over a quick exit and is willing to forgo near-term returns to get there. They are not opposites, and they are not the same axis — which is why the more useful question for a founder is not "growth or patient?" but "does this money match the stage my business is at and the time horizon I need?" Get that match wrong and even well-intentioned capital can push you toward a premature exit or a loss of control. Get it right and the capital funds the scale-up you actually planned.

What growth capital is

Growth capital — sometimes called growth equity — is a recognised stage of private investment that sits between venture capital and a buyout. UK Private Capital, the industry body formerly known as the BVCA, describes private equity as medium-to-long-term finance provided in return for an equity stake in companies with growth potential, and lists an expansion or growth stage explicitly: capital for profitable, operating companies expanding their markets, products or capacity.

The defining features matter for a founder. Growth capital usually takes a minority stake, which means the founders and management keep day-to-day control and strategic decision-making; the investor's rights tend to be consent or veto over major actions rather than the power to make changes directly. It targets companies that are already established and generally profitable — distinct from venture capital, which backs early-stage, often pre-profit businesses, and from a buyout, where an investor acquires control outright. The money funds a defined plan: a new market, a product line, an acquisition, or the working capital to support a step-change in demand. Exit typically comes once those growth targets are met, through a sale, a share buyback or, less often, an IPO.

What patient capital is

Patient capital is defined less by structure and more by behaviour: a long time horizon and a willingness to back sustainable growth over a quick return. In the UK it has a specific origin. In 2016 the government launched the Patient Capital Review, led by HM Treasury with an independent panel chaired by Sir Damon Buffini, to examine why high-growth, knowledge-intensive British firms struggled to access the long-term finance they needed to scale up.

The review's diagnosis was blunt: there was a shortage of patient capital, a gap it estimated in the order of several billion pounds a year, and it was most acute for companies needing more than £5 million in equity to grow. The conclusion fed into a ten-year action plan and, in 2018, the launch of British Patient Capital — a £2.5 billion programme within the British Business Bank, created specifically to enable long-term investment in ambitious, innovative UK companies. The thread running through all of it is the willingness to stay invested through the long arc of building something, rather than optimising for an early liquidity event. That intent — not a particular deal structure — is what makes capital "patient."

Why "growth vs patient" is the wrong question

Here is the distinction the comparison usually misses. Growth capital answers what stage and structure the money takes — an established company, a minority equity position. Patient capital answers how long and with what intent the money is held. They are different axes, and they overlap freely. You can raise growth capital that is deeply impatient, with a tight exit clock and pressure to sell within a few years. You can also find patient capital structured as early-stage venture rather than growth. British Patient Capital itself backs both venture and growth funds — proof that "patient" is a description of intent, not a separate asset class.

So a founder who frames the decision as "should I take growth capital or patient capital?" is comparing a stage to a temperament. The sharper approach is to match two things independently: the stage and structure your business needs — which depends on how established and profitable you are — and the time horizon and intent of the specific investor sitting across the table. The label on the fund matters far less than the answers to those two questions.

The dimensions that actually decide

When the framing is right, the comparison becomes concrete. A few dimensions do most of the deciding.

Time horizon and exit pressure. Does the investor expect a defined exit on a set clock, or are they genuinely long-term? Growth equity and venture funds often work to a holding period of several years with a planned exit; patient investors are willing to wait. This is the single dimension most likely to determine whether the relationship serves your plan or fights it.

Control and dilution. More capital usually means more dilution and more say given away. Harvard Business School's Noam Wasserman, who studied hundreds of founder decisions, framed it as a choice between being "rich" and being "king": the capital that builds the most value often comes at the cost of control, and outside investors can, through board seats and shareholder rights, ultimately replace even the founder. Growth capital's minority structure is attractive here precisely because it tends to leave operational control with the founder.

Governance and involvement. Board seats, veto rights and reporting obligations vary widely. Some investors are hands-off; others are closely involved. Neither is wrong — but a founder should know which they are getting, and whether the involvement comes with useful operational help or only oversight.

Stage fit. Early and pre-profit points to venture; established and profitable points to growth capital; a full handover of ownership points to a buyout. Matching the instrument to where the business actually is keeps you from raising the wrong kind of money for your maturity.

Which fits a scaling founder?

For most founders at the scale stage — established, generating revenue, and wanting to fund a clear expansion without handing over the company — growth capital is the natural structural fit, because it provides meaningful funding while leaving control in their hands. The harder question is intent: a founder building for the long term is poorly served by growth capital that comes with a short fuse, however attractive the headline cheque. The combination worth holding out for is growth-stage funding carried by a patient temperament — capital that matches your maturity and your time horizon.

It is also worth remembering that capital alone rarely settles the outcome. As we have argued, capital does not fail businesses — weak foundations do. The money is only as good as the structure it lands on, which is why the strongest founders raise after they have built the business that can carry it, not before.

How Nordhaven fits

Nordhaven provides growth capital structured around founders, deliberately designed so they do not lose control — and we back it with hands-on operational partnership rather than passive money. In practice that means we behave patiently, because we are there to help build, not to force an early exit. For one executive-led startup, that took the form of funding plus a twelve-month runway while we ran the operational core — marketing, IT, compliance and finance — so the founders could put their attention on growth. That is what "more than capital" looks like in the dimensions above: minority structure, founder control, a long horizon, and real operational involvement.

The honest guidance for a founder weighing growth capital against patient capital is to stop treating them as rival products and start treating them as two questions: what stage and structure do I need, and how long is this investor prepared to wait? When the answers line up — and the capital comes with people who have run the functions you are trying to scale — the choice stops being a trade-off and becomes a fit. That is the partnership we aim to be, and the work behind scaling a business without breaking it.

Frequently asked questions

What is meant by patient capital? Patient capital is long-term investment — debt or equity — where the investor prioritises sustainable, long-term growth over a quick return and is willing to forgo near-term gains and a fast exit. It is defined by time horizon and intent rather than by a specific deal structure. In the UK it stems from HM Treasury's 2017 Patient Capital Review.

What is the difference between growth capital and patient capital? Growth capital describes a stage and structure: a usually minority, non-control equity investment in an established, profitable company to fund expansion. Patient capital describes a time horizon and intent: a willingness to stay invested for the long term. They are different dimensions — capital can be both, either, or neither.

Is patient capital better for founders? Not automatically — it depends on the match. A founder building for the long term benefits from an investor who will not force a premature exit. But "patient" intent still has to come with the right stage and structure (and ideally operational help). The best fit aligns time horizon, control and stage at once.

What is an example of patient capital? British Patient Capital — a £2.5 billion programme launched in 2018 within the UK's British Business Bank — is a clear example. It was created in response to the Patient Capital Review to provide long-term investment in ambitious, innovative UK companies through venture and growth funds.